+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Diabetic Gastroparesis Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767538
  • Report
  • April 2019
  • Region: Global
  • 64 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • AlfaSigma SpA
  • Allergan Plc
  • Catalyst Biosciences Inc
  • Eli Lilly and Company
  • Evoke Pharma Inc
  • GlaxoSmithKline Plc
  • MORE
The global clinical trial report- “2019 Diabetic Gastroparesis Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Diabetic Gastroparesis. It presents in-depth analysis of Diabetic Gastroparesis clinical trials across markets and companies. The research work is for providing complete understanding into trends in Diabetic Gastroparesis.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Diabetic Gastroparesis clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Diabetic Gastroparesis

The research work is prepared through extensive and continuous research on Diabetic Gastroparesis trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Diabetic Gastroparesis patients are identified
  • The report includes panorama of Diabetic Gastroparesis clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Diabetic Gastroparesis clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AlfaSigma SpA
  • Allergan Plc
  • Catalyst Biosciences Inc
  • Eli Lilly and Company
  • Evoke Pharma Inc
  • GlaxoSmithKline Plc
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Diabetic Gastroparesis Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Diabetic Gastroparesis Clinical Trials by Region
2.2.2 Average Enrollment of Diabetic Gastroparesis Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Diabetic Gastroparesis Treatment, 2019

3. Region wise Diabetic Gastroparesis Clinical Trials
3.1 Asia Pacific Diabetic Gastroparesis Clinical Trials by Country
3.2 Europe Diabetic Gastroparesis Clinical Trials by Country
3.3 North America Diabetic Gastroparesis Clinical Trials by Country
3.4 Middle East and Africa Diabetic Gastroparesis Clinical Trials by Country
3.5 South and Central America Diabetic Gastroparesis Clinical Trials by Country

4. Diabetic Gastroparesis Clinical Trial Trends
4.1 Start Year wise Diabetic Gastroparesis Clinical Trials
4.2 Phase wise Diabetic Gastroparesis Clinical Trials
4.3 Trial Status wise Diabetic Gastroparesis Clinical Trials
4.4 Trial Type wise Diabetic Gastroparesis Clinical Trials

5. Diabetic Gastroparesis Average Enrollment Trends
5.1 Average Enrollment in Diabetic Gastroparesis Trials by Year
5.2 Average Enrollment in Diabetic Gastroparesis Trials by Phase
5.3 Average Enrollment in Diabetic Gastroparesis Trials by Status
5.4 Average Enrollment in Diabetic Gastroparesis Trials by Type of Trial

6. Companies Participating in Diabetic Gastroparesis Clinical Trials
6.1 Diabetic Gastroparesis Trials by Sponsor Type
6.2 Diabetic Gastroparesis Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Diabetic Gastroparesis Trials- Phase 1
7.2 Diabetic Gastroparesis Trials- Phase 2
7.3 Diabetic Gastroparesis Trials- Phase 3
7.4 Diabetic Gastroparesis Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Diabetic Gastroparesis Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Diabetic Gastroparesis Clinical Trials and Enrolment
Figure 5: Europe - Country wise Diabetic Gastroparesis Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Diabetic Gastroparesis Clinical Trials and Enrolment
Figure 7: North America - Country wise Diabetic Gastroparesis Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Diabetic Gastroparesis Clinical Trials and Enrolment
Figure 9: Diabetic Gastroparesis Clinical Trials by Phase
Figure 10: Diabetic Gastroparesis Clinical Trials by Trial Status
Figure 11: Diabetic Gastroparesis Clinical Trials by Type
Figure 12: Diabetic Gastroparesis Clinical Trials by Sponsor Type
Figure 13: Diabetic Gastroparesis Clinical Trials by Leading Sponsors
Figure 14: Diabetic Gastroparesis Average Enrollment by Phase
Figure 15: Diabetic Gastroparesis Average Enrollment by Trial Status
Figure 16: Diabetic Gastroparesis Average Enrollment by Type
Figure 17: Diabetic Gastroparesis- Average Enrolment by Type of Sponsors
Figure 18: Diabetic Gastroparesis- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Diabetic Gastroparesis Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Diabetic Gastroparesis Clinical Trials and Enrolment
Table 5: Europe - Country wise Diabetic Gastroparesis Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Diabetic Gastroparesis Clinical Trials and Enrolment
Table 7: North America - Country wise Diabetic Gastroparesis Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Diabetic Gastroparesis Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Diabetic Gastroparesis Average Enrollment by Phase
Table 15: Diabetic Gastroparesis Average Enrollment by Trial Status
Table 16: Diabetic Gastroparesis Average Enrollment by Type
Table 17: Diabetic Gastroparesis- Average Enrolment by Type of Sponsors
Table 18: Diabetic Gastroparesis- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3
  • AlfaSigma SpA
  • Allergan Plc
  • Catalyst Biosciences Inc
  • Eli Lilly and Company
  • Evoke Pharma Inc
  • GlaxoSmithKline Plc
  • ICON Plc
  • Ironwood Pharmaceuticals Inc
  • Ocera Therapeutics Inc
  • Rhythm Holding Company LLC
Note: Product cover images may vary from those shown
Adroll
adroll